Randomized phase II trial of uracil/tegafur and cisplatin versus vinorelbine and cisplatin with concurrent thoracic radiotherapy for locally advanced unresectable stage III non-small-cell lung cancer: NJLCG 0601
Shunichi Sugawara(Sendai Kousei Hospital), Toshihiro Nukiwa(Tohoku University), Motoko Tachihara(Kobe University), Akira Inoue(Tohoku University Hospital), Takashi Ishida(Keio University), Tomohiro Sakakibara(Tohoku University Hospital), Hiroshi Watanabe(Tohoku University), Yasuo Saijo(Ho Chi Minh City International University), Kazuhiro Usui(Hokkaido University Hospital), Kenya Kanazawa(Fukushima Medical University), Kana Watanabe(Miyagi Prefectural Hospital Organization), Osamu Ishimoto(Sendai Kousei Hospital), Nobumichi Matsubara(Miyagi Prefectural Hospital Organization), Makoto Maemondo(Miyagi Prefectural Hospital Organization)
Cited by 28
Related Papers
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
|New England Journal of Medicine|2010|5.6k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
|The Lancet|2021|1.5k
Nrf2 Redirects Glucose and Glutamine into Anabolic Pathways in Metabolic Reprogramming
|Cancer Cell|2012|1.4k
Double-blind, Placebo-controlled Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis
|American Journal of Respiratory and Critical Care Medicine|2005|953